| Home | Log In | Register | Our Services | My Account | Contact | Help |
ANGLE - Share price 86p broker target 165p - SIGNIFICANTLY UNDERVALUED (AGL)
thorhildur - 29 Jan 2006 11:45
Collins Stewart gives a target valuation for the combined entity of 26 million or 156p per share
Edison Investments embedded valuation is 31m - Indicating a 100% gain in share price from current levels. They suggest that using the current embedded valuation model, the current value of Angles six non-exited ventures is only 5.5m - suggesting Angle to be SIGNIFICANTLY UNDERVALUED
Have a look
required field - 25 Sep 2014 21:12 - 154 of 195
skinny
- 27 Jan 2015 07:16
- 155 of 195
required field - 27 Jan 2015 15:41 - 156 of 195
skinny
- 27 Jan 2015 15:43
- 157 of 195
kimoldfield
- 27 Jan 2015 16:02
- 158 of 195
required field - 27 Jan 2015 16:03 - 159 of 195
kimoldfield
- 27 Jan 2015 16:57
- 160 of 195
mitzy - 27 Jan 2015 19:26 - 161 of 195
skinny
- 28 Jan 2015 06:57
- 162 of 195
required field - 28 Jan 2015 09:17 - 163 of 195
skinny
- 29 Jan 2015 07:19
- 164 of 195
MOVING CLOSER TO A CLINICAL APPLICATION
ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, today announces unaudited interim results for the six months ended 31 October 2014.
Highlights
· Collaboration agreements signed with a further five leading international cancer research centres bringing the total number of key opinion leaders working with the Parsortix system to eight covering the UK, Europe and the United States collectively covering breast, colorectal, oesophageal, ovarian, prostate and pancreatic cancers
· Four of the key opinion leaders publicly reported during the period bringing a total of five key opinion leaders reporting positively on their evaluation of the Parsortix system. The remaining three are in progress
· Continued progress towards FDA authorisation
· Second US patent granted relating to improvements in technology and specific use for foetal and cancer applications
· Management team strengthened with US specialist medtech commercialisation experience
· Loss for the half year of £1.6 million (H1 2014: loss £0.5 million) reflecting planned investment in Parsortix of £1.6 million (H1 2014: £1.1 million)
· Cash balance at 31 October 2014 of £2.3 million (30 April 2014: £3.9 million)
Progress post the half year end
· Commercial collaboration established with the diagnostics division of a large pharmaceutical company to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform as a front end to the Collaborator's single cell analysis system
· Commercial collaboration established with EKF Diagnostics Holdings plc to investigate the combination of ANGLE's Parsortix circulating tumour cell (CTC) harvesting platform with EKF's PointMan™ DNA enrichment technology as a liquid biopsy to provide a combined solution
· Patient study provides basis for clinical application in ovarian cancer with the Medical University of Vienna reporting the Parsortix system delivers "unprecedented sensitivity and specificity". Following these excellent results in ovarian cancer, ANGLE has commenced a process, in collaboration with the Medical University of Vienna to develop a clinical application for ovarian cancer.
required field - 09 Feb 2015 10:08 - 165 of 195
required field - 23 Feb 2015 09:56 - 166 of 195
Bullshare
- 20 Mar 2015 16:36
- 167 of 195
Shares Investor Evenings is going to Manchester, we will showcase four leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsTuesday 31st March 2015
Venue:Lancashire County Cricket Club, Manchester, Emirates Old Trafford, Talbot Road, Manchester, M16 0PX
Event Timings:| 18.00 | Registration and coffee | |
| 18.30 | Presentations • Neil O'Brien, CEO - Alkane Energy (ALK:AIM) • Andrew Newland, CEO - Angle (AGL:AIM) • Dr Satu Vainikka, Chief Executive Officer - Valirx (VAL:AIM) • Martin Perrin, Chief Financial Officer - Vipera (VIP:AIM) | |
| 20.30 | Drinks reception and canapés | |
| 21.30 | Close |
 | Alkane Energy is one of the UK’s fastest growing independent power generators. The Company operates mid-sized 'gas to power' electricity plants providing both predictable and fast response capacity to the grid. Alkane now has a total of 140MW of installed generating capacity and an electricity grid capacity of 160MW. |
 | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. In December 2013, ANGLE secured CE Mark regulatory authorisation for the clinical market in 2013 and FDA approval is planned for 2014. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: • Early detection of cancer;• Personalised cancer treatment;• Monitoring of cancer patients during treatment; and• Post-treatment monitoring of cancer patients in remission. |
 | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
 | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |
required field - 25 Mar 2015 09:24 - 168 of 195
required field - 21 Apr 2015 09:00 - 169 of 195
required field - 24 Apr 2015 13:00 - 170 of 195
required field - 29 Apr 2015 11:25 - 171 of 195
required field - 30 Apr 2015 10:33 - 172 of 195
skinny
- 11 May 2015 15:24
- 173 of 195
| About MoneyAM | Ts and Cs | Privacy Policy | Investment Warning | Content Standards | Corporate Solutions | Advertise With Us | Site Map | © 2025 MoneyAM |
Follow us on Twitter